Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
MAZANOR (mazindol) is an oral anorectic agent approved in 1980 for weight management. It is a sympathomimetic amine that stimulates the central nervous system to reduce appetite. The drug is indicated for short-term adjunctive therapy in exogenous obesity.
Approaching loss of exclusivity with low current team activity; brand faces significant competitive pressure (30/100) in the crowded weight management space.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Worked on MAZANOR at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Zero linked job openings indicate minimal active hiring for this product. Working on MAZANOR offers limited career momentum in a declining franchise with few growth opportunities and likely budget constraints.